We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
The treatment of multiple sclerosis, with the first treatments that appeared at the beginning of the 1990s, has allowed the natural history of the disease to change. The proportion of disabled people is getting smaller and smaller. However, there is a long way to go when it comes to treating the clinical presentation and progressive physiopathology that can be related to the disease.
At present, the challenge is to offer the appropriate drug for patients, i.e. ‘personalised’ or ‘precision medicine.’ It is also key to quickly detect patients who do not respond to a specific treatment. This is why there are different ways of addressing the disease.
Primary treatment line or moderate efficacy treatments:
These types of treatment are indicated in patients with low inflammatory load, in whom it is expected to control inflammation with drugs of moderate effectiveness. These are drugs that have an acceptable safety profile, with adverse effects that are usually mild. Deciding between different front-line drugs depends on the method of administration, the profile of adverse effects, gestational desire or the patient’s medical history. You can find:
Second line of treatment or highly effective treatment:
In this case, treatments are indicated in patients with high inflammatory load or persistent inflammation, despite moderate treatment. These are drugs that can potentially cause adverse effects such as systemic or central nervous system infections. The choice of drugs is based on the safety profile, gestational desire, pathological history and degree of inflammation of patients. The most common are:
Treatment due to progression with inflammatory activity:
There are two specific medications: ocrelizumab is used in patients with progressive multiple sclerosis, the only progressively available treatment, while siponimod is used in patients with progression after a remission-recurring phase.
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.